Medication finds new use in sustaining opioid quit success | National Institute on Drug Abuse (NIDA)

prescription-bottles

Medication finds new use in sustaining opioid quit success | National Institute on Drug Abuse (NIDA)

New research suggests that clonidine, a medication for high blood pressure and attention deficit hyperactivity disorder (ADHD), can enhance buprenorphine’s ability to treat opioid dependence. This combination of medications reduces stress-induced craving and prolongs opioid abstinence during outpatient treatment for heroin or prescription pain reliever dependence, compared to buprenorphine alone.

These results show that clonidine, when combined with buprenorphine, could be another tool for clinicians who are treating patients in recovery from opioid misuse.

(NIDA) is a component of the National Institutes of Health, U.S. Department of Health and Human Services. NIDA supports most of the world’s research on the health aspects of drug abuse and addiction. The Institute carries out a large variety of programs to inform policy and improve practice. Fact sheets on the health effects of drugs of abuse and information on NIDA research and other activities can be found at

, which is now compatible with your smartphone, iPad or tablet. To order publications in English or Spanish, call NIDA’s DrugPubs research dissemination center at 1-877-NIDA-NIH or 240-645-0228 (TDD) or email requests to

NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit

 

Curated: Medication finds new use in sustaining opioid quit success | National Institute on Drug Abuse (NIDA)

 

Share the Post

About the Author

Comments

Comments are closed.